Other Species / Isoforms
  RRAD (mouse)      LTP 

LTP (Low Throughput Papers) : The number of records in which this modification site was determined using methods other than discovery mass spectrometry.

 HTP 

HTP (High Throughput Papers): The number of records in which this modification site was assigned using ONLY proteomic discovery mass spectrometry.

 
T2-p
______MtLNGGSGA
0 1
RRAD (human) ______MTLNGGGSG T2
RRAD (mouse) ______MtLNGGSGA T2-p
RRAD (rat) ______MTLNGGSGA T2
R13
GSGASGSRGAGGRER
0 1
RRAD (human) GSGAGGSrGGGQERE R14-m1
RRAD (mouse) GSGASGSRGAGGRER R13
RRAD (rat) GSGAGGSRSAGRERD R13
R24-m1
GRERDRRrGstPWGP
0 3
RRAD (human) GQERERRRGstPWGP R24
RRAD (mouse) GRERDRRrGstPWGP R24-m1
RRAD (rat) GRERDRRRGSTPWGP R23
S26-p
ERDRRrGstPWGPAP
Upstream
Downstream
1 7
Effects on Modified Protein
  • activity, induced
  • molecular association, regulation
Putative in vivo kinases:
  • PKACA (human)
Treatment
  • insulin
  • NKH_477
RRAD (human) ERERRRGstPWGPAP S26-p
RRAD (mouse) ERDRRrGstPWGPAP S26-p
RRAD (rat) ERDRRRGSTPWGPAP S25
T27-p
RDRRrGstPWGPAPP
Upstream
0 3
Treatment
  • insulin
RRAD (human) RERRRGstPWGPAPP T27-p
RRAD (mouse) RDRRrGstPWGPAPP T27-p
RRAD (rat) RDRRRGSTPWGPAPP T26
S39-p
APPLHRRsMPVDERD
Upstream
Downstream
1 16
Effects on Modified Protein
  • activity, induced
  • molecular association, regulation
Putative in vivo kinases:
  • PKACA (human)
Treatment
  • NKH_477
RRAD (human) APPLHRRsMPVDERD S39-p
RRAD (mouse) APPLHRRsMPVDERD S39-p
RRAD (rat) APPLHRRsMPVDERD S38-p
A52
RDLQAALAPGSLATT
0 1
RRAD (human) RDLQAALtPGALTAA T52-p
RRAD (mouse) RDLQAALAPGSLATT A52
RRAD (rat) RDLQAALTPGSLAAT T51
S79
WPEGSSDSLSSGGSG
0 1
RRAD (human) WPEDSEDsLSSGGSD S79-p
RRAD (mouse) WPEGSSDSLSSGGSG S79
RRAD (rat) WPEGSSDSLSSGDSG S78
S105-p
GAPGVGKsALARIFG
0 1
RRAD (human) GAPGVGKSALARIFG S105
RRAD (mouse) GAPGVGKsALARIFG S105-p
RRAD (rat) GAPGVGKSALARIFG S104
K204
PIILVGNKSDLVRSR
0 2
RRAD (human) PIILVGNkSDLVRSR K204-ub
RRAD (mouse) PIILVGNKSDLVRSR K204
RRAD (rat) PIILVGNKSDLVRSR K203
S214
LVRSREVSVDEGRAC
1 0
RRAD (human) LVRSREVsVDEGRAC S214-p
RRAD (mouse) LVRSREVSVDEGRAC S214
RRAD (rat) LVRSREVSVDEGRAC S213
S257
QIRLRRDSKEDNARR
1 0
RRAD (human) QIRLRRDsKEANARR S257-p
RRAD (mouse) QIRLRRDSKEDNARR S257
RRAD (rat) QIRLRRDSKEDNARR S256
S273-p
AGTRRREsLGKKAKR
2 1
RRAD (human) AGTRRREsLGKKAKR S273-p
RRAD (mouse) AGTRRREsLGKKAKR S273-p
RRAD (rat) AGTRRRESLGKKAKR S272
S290-p
GRIVARNsRKMAFRA
1 1
RRAD (human) GRIVARNsRKMAFRA S290-p
RRAD (mouse) GRIVARNsRKMAFRA S290-p
RRAD (rat) GRIVARNSRKMAFRA S289
S299-p
KMAFRAKsKsCHDLS
Downstream
2 2
Effects on Modified Protein
  • intracellular localization
  • molecular association, regulation
RRAD (human) KMAFRAKsKsCHDLS S299-p
RRAD (mouse) KMAFRAKsKsCHDLS S299-p
RRAD (rat) KMAFRAKSKSCHDLS S298
S301-p
AFRAKsKsCHDLSVL
Upstream
Downstream
1 17
Effects on Modified Protein
  • activity, induced
  • molecular association, regulation
Putative in vivo kinases:
  • PKACA (human)
Treatment
  • NKH_477
RRAD (human) AFRAKsKsCHDLSVL S301-p
RRAD (mouse) AFRAKsKsCHDLSVL S301-p
RRAD (rat) AFRAKSKSCHDLSVL S300